Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BOLAR APPOINTS SHAROKY PRESIDENT AND CEO

Executive Summary

BOLAR APPOINTS SHAROKY PRESIDENT AND CEO of the Copiague, N.Y.-based generic drug company effective Jan. 31, 1993, Bolar said Dec. 11. Forty-two year old Seymour Sharoky, MD, is currently Exec VP-R&D. He originally came to the company from the Baltimore- based contract testing firm PharmaKinetics in 1988 and took over responsibility for clinical development at Bolar. Sharoky will take over the positions following the "resignation of Lawrence Raisfeld as President and Chief Executive Officer effective Jan. 31, 1993," Bolar said. The company said that "this is not connected to the generic drug scandal or to recent antitrust investigations." On Dec. 9 former Bolar president Robert Shulman was charged with conspiring to fix the price of generic Dyazide (see following T&G). Raisfeld, a cofounder of Bolar with Shulman in 1959, became president when Shulman resigned in February 1990 due to fraud charges ("The Pink Sheet" Feb. 19, 1990, p. 12). In addition to gaining the top positions at Bolar, Sharoky has "become a director of the company on the resignation from the board of Seymour Inkles," Bolar said. In the weeks following Shulman's resignation, Inkles was shuffled from his director of scientific affairs post to acting head of R&D and then to president, scientific affairs ("The Pink Sheet" March 5, 1990, T&G-14).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel